Market Place
Sourcing Support
Leica Biosystems Expands Collaboration on AI-Powered Diagnostics
03 Jun 2026 //
PRESS RELEASE
Daiichi Sankyo Showcases Oncology Portfolio at ASCO 2026
28 May 2026 //
BUSINESSWIRE
Daiichi Sankyo Signs pCPA Letter of Intent for Vanflyta
28 May 2026 //
BIOSPACE
Daiichi-Fortis Case: Court Reserves Judgment After 50 Hearings
27 May 2026 //
ECONOMICTIMES
Daiichi Sankyo Europe Showcases Data at EAS Congress 2026
26 May 2026 //
BUSINESSWIRE
CHMP Backs Enhertu for Previously Treated HER2+ Solid Tumors
22 May 2026 //
BUSINESSWIRE
Datroway Approved as 1st ADC for 1L Triple-Negative Breast Cancer
22 May 2026 //
BUSINESSWIRE
Daiichi Emerges from 2 Tough Years with Vision for Cancer Care
19 May 2026 //
BIOSPACE
Enhertu Adds Two More Breast Cancer Indications To Its US Label
15 May 2026 //
FDA
Daiichi Sankyo Unveils 5-Year Business Plan for Oncology Growth
11 May 2026 //
BUSINESSWIRE
Daiichi Eyes Almost $15B in Oncology Sales by 2030 in ADC Push
10 May 2026 //
ENDPOINTS
Daiichi Sankyo Posts `Extraordinary Loss` Of Nearly $1B
08 May 2026 //
ENDPOINTS
Waiv Collaborates with Daiichi Sankyo on AI Biomarkers for ADC
06 May 2026 //
BUSINESSWIRE
Tokyo Court To Rule On Fortis Arm IHH And Daiichi Sankyo Dispute
29 Apr 2026 //
ECONOMICTIMES
IHH Seeks Mitsui Aid for ?11,800 Cr Daiichi Deal
28 Apr 2026 //
ECONOMICTIMES
Daiichi Sankyo Shares Slip After Delaying Annual Earnings Report
24 Apr 2026 //
BIOSPACE
Interna Therapeutics Collaborates With Daiichi Sankyo
16 Apr 2026 //
PR NEWSWIRE
Daiichi Sankyo Names Global Chief Corporate Affairs Officer
16 Apr 2026 //
FIRSTWORD PHARMA
Daiichi Sankyo plots $1.5B consumer health unit sale to Suntory
16 Apr 2026 //
PRESS RELEASE
Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo
15 Apr 2026 //
FIRSTWORD PHARMA
4D Path, Daiichi Sankyo Partner on AI Biomarkers for ADC
14 Apr 2026 //
BUSINESSWIRE
Daiichi Sankyo`s Ifinatamab Deruxtecan Gets Priority Review
14 Apr 2026 //
PHARMIWEB
Imagene AI Daiichi Sankyo Partner To Advance Oncology Biomarker
09 Apr 2026 //
PHARMIWEB
ATLATL, Daiichi Sankyo Partner to Boost APAC Biotech
08 Apr 2026 //
PR NEWSWIRE
Nuvation Bio Acquires Japan Rights to Safusidenib from Daiichi
01 Apr 2026 //
PR NEWSWIRE
Leveragen, Daiichi Sankyo Partner on In Vivo Antibody Platforms
18 Mar 2026 //
PHARMIWEB
Voro Therapeutics Announces Research Collaboration With Daiichi
17 Mar 2026 //
BUSSINESSWIRE
Daiichi Sankyo, AZ`s Enhertu wins US priority review
09 Mar 2026 //
FIERCE PHARMA
Daiichi pens Pact for High Cholesterol Digital Therapeutic
05 Mar 2026 //
FIERCE BIOTECH
Sylamorebio Collab With Daiichi On Sylec Delivery Technology
23 Feb 2026 //
PHARMIWEB
Daiichi Sankyo Appoints John Tsai, MD as Global Head of R&D
19 Feb 2026 //
BUSINESSWIRE
OX40, Roche-Sanegene, Daiichi—Fierce Pharma Asia
06 Feb 2026 //
FIERCE PHARMA
DS3790 Enters Clinic as First DXd ADC in Hematology by Daiichi
04 Feb 2026 //
BUSINESSWIRE
FDA Priority Review for DATROWAY for Metastatic Breast Cancer
03 Feb 2026 //
BUSINESSWIRE
Daiichi Stops Internal Development Of Next-Wave ADC
02 Feb 2026 //
FIERCE BIOTECH
Daiichi Sankyo Navigates Complexity of Success
27 Jan 2026 //
FIERCE PHARMA
Daiichi Sankyo Navigates Complexity Of Success
26 Jan 2026 //
FIERCE PHARMA
Daiichi Sankyo Appoints Leaders at European Translational Center
22 Jan 2026 //
BUSINESSWIRE
ENHERTU + Pertuzumab EU Filing Validated for HER2+ Breast Cancer
19 Jan 2026 //
BUSINESSWIRE
ENHERTU Plus Pertuzumab EU Type II Variation Validated
19 Jan 2026 //
BUSINESSWIRE
FDA Lifts Hold On Merck, Daiichi`s Lung Cancer ADC Trial
13 Jan 2026 //
BIOSPACE
DATROWAY Ph 3 TROPION-Lung17 Trial Initiated in NSCLC Cancer
13 Jan 2026 //
BUSINESSWIRE
Tempus Achieves Record Total Contract Value Exceeding $1.1 B
11 Jan 2026 //
BUSINESSWIRE
Daiichi taps Genesis to help market Vanflyta in Europe
07 Jan 2026 //
PHARMIWEB
Daiichi to Boost Production with $1.9B in Investments
05 Jan 2026 //
FIERCE PHARMA
ENHERTU Launches Adjuvant Phase 3 Trial in HER2+ Endometrial
22 Dec 2025 //
BUSINESSWIRE
FDA Grants ENHERTU BTD for HER2+ Early Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
FDA OKs ENHERTU Breakthrough Designation for HER2+ Breast Cancer
22 Dec 2025 //
BUSINESSWIRE
EU Validates DATROWAY for First-Line Metastatic Treatment
18 Dec 2025 //
BUSINESSWIRE
Daiichi-Merck Ph. 3 ADC Program On Pause After Patient Deaths
18 Dec 2025 //
FIERCE BIOTECH
FDA Approves Roche`s ENHERTU for HER2+ Metastatic Breast Cancer
16 Dec 2025 //
PR NEWSWIRE
Lunit, Daiichi Sankyo Partner To Advance Ai Biomarker Discovery
15 Dec 2025 //
PR NEWSWIRE
FDA Approves AZ/Daiichi`s Enhertu in 1st-Line Breast Cancer
15 Dec 2025 //
BUSINESSWIRE
Therapy Eases Side Effects for 75% of Black Breast Cancer
10 Dec 2025 //
BUSINESSWIRE
DESTINY-Ovarian01—ENHERTU Phase 3 Begins for HER2+Ovarian Cancer
09 Dec 2025 //
BUSINESSWIRE
Daiichi Sankyo Highlights ADC Portfolio In Breast Cancer Trials
08 Dec 2025 //
BUSINESSWIRE
FDA Letter To Daiichi Takes Aim At Turalio Patient Video
04 Dec 2025 //
FIERCE PHARMA
Daiichi Prevails On Appeal In ADC Patent Battle With Seagen
04 Dec 2025 //
FIERCE PHARMA
Allegro, American Regent Sign 35M Synoglide Deal in Animal Health
25 Nov 2025 //
GLOBENEWSWIRE
Daiichi Sankyo Initiates First Human Trial For Cancer Therapy
14 Nov 2025 //
INDPHARMAPOST
